 prospect trial epirubicin monochemotherapi fluorouracil cyclophosphamid epirubicin regimen epirubicin dose advanc breast cancer patient french epirubicin studi group french epirubicin studi group random trial fluorouracil fec fec first treatment advanc breast cancer patient patient bone metastas twelv patient trial assess toler efficaci overal respons rate compar fec epirubicin complet respons rate fec fec epirubicin similar result group patient bone-onli metastas differ treatment patient bone metastas mean durat respons similar group day day day fec fec patient previou adjuv chemotherapi previou treatment anthracyclin toler group overal epirubicin-alon group toler group time progress surviv differ group earli relaps epirubicin fec group surviv first month fec group surviv differ epirubicin group fec group borderlin signific differ surviv epirubicin- fec patient respons rate monochemotherapi group